Sandy Mahatme

Sandy Mahatme was most recently the Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, from Nov 2012 through July 2020, where he headed Sarepta’s finance, business development, technical operations, facilities, IT, and investor and public relations functions. During his tenure, Sarepta’s employee base grew from around 100 to over 700 employees, its pipeline from nine to over 40 programs in various stages of development, and its footprint of a single location in Cambridge, Massachusetts to over a dozen locations across the U.S. and around the world. Sandy played an instrumental role in this growth, and he’s personally led a number of Sarepta’s strategic manufacturing deals.

From January 2006 to November 2012, Sandy worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including senior vice president of corporate development, senior vice president of finance, corporate treasurer, and head of tax. While at Celgene, Sandy built the treasury and tax functions before establishing the corporate development department focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing, and global manufacturing expansion. Prior to working at Celgene, Sandy worked for Pfizer for eight and a half years in senior roles in business development and corporate tax. Sandy started his career at Ernst & Young, where he advised multinational corporations on a broad range of transactions. Sandy holds Master of Laws (LL.M.) degrees from Cornell Law School and New York University School of Law and is a member of the New York State Bar Association. Sandy is also a member of the Boards of Directors of biopharmaceutical companies Idorsia Pharmaceuticals, Aeglea BioTherapeutics, and Flexion Therapeutics.